JP6878423B2 - プラスミノーゲン欠損症のためのプラスミノーゲン補充療法 - Google Patents

プラスミノーゲン欠損症のためのプラスミノーゲン補充療法 Download PDF

Info

Publication number
JP6878423B2
JP6878423B2 JP2018522753A JP2018522753A JP6878423B2 JP 6878423 B2 JP6878423 B2 JP 6878423B2 JP 2018522753 A JP2018522753 A JP 2018522753A JP 2018522753 A JP2018522753 A JP 2018522753A JP 6878423 B2 JP6878423 B2 JP 6878423B2
Authority
JP
Japan
Prior art keywords
plasminogen
activity
subject
normal
plasminogen activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018522753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533589A (ja
JP2018533589A5 (enExample
Inventor
マルタン・ロビタイユ
カレン・チボドー
ピエール・ローラン
ステイシー・プラム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometic Biotherapeutics Inc
Original Assignee
Prometic Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Inc filed Critical Prometic Biotherapeutics Inc
Publication of JP2018533589A publication Critical patent/JP2018533589A/ja
Publication of JP2018533589A5 publication Critical patent/JP2018533589A5/ja
Application granted granted Critical
Publication of JP6878423B2 publication Critical patent/JP6878423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018522753A 2015-11-03 2016-11-03 プラスミノーゲン欠損症のためのプラスミノーゲン補充療法 Active JP6878423B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250235P 2015-11-03 2015-11-03
US62/250,235 2015-11-03
PCT/IB2016/001599 WO2017077380A1 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Publications (3)

Publication Number Publication Date
JP2018533589A JP2018533589A (ja) 2018-11-15
JP2018533589A5 JP2018533589A5 (enExample) 2019-12-12
JP6878423B2 true JP6878423B2 (ja) 2021-05-26

Family

ID=58661917

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018522753A Active JP6878423B2 (ja) 2015-11-03 2016-11-03 プラスミノーゲン欠損症のためのプラスミノーゲン補充療法

Country Status (16)

Country Link
US (1) US11291711B2 (enExample)
EP (1) EP3370760B1 (enExample)
JP (1) JP6878423B2 (enExample)
KR (1) KR102821400B1 (enExample)
CN (1) CN108289935A (enExample)
AU (1) AU2016347863B2 (enExample)
BR (1) BR112018008965A8 (enExample)
CA (1) CA3002915C (enExample)
FI (1) FI3370760T3 (enExample)
IL (1) IL258913B (enExample)
MX (1) MX2018005588A (enExample)
MY (1) MY199581A (enExample)
RU (1) RU2736831C2 (enExample)
TW (1) TWI801331B (enExample)
WO (1) WO2017077380A1 (enExample)
ZA (1) ZA201802820B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
WO2017101866A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
CN108778320A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗心血管病的新方法
CA3008694C (en) 2015-12-18 2022-11-29 Talengen International Limited Use of plasminogen for preventing or treating diabetic nerve injury and related disorders thereof
WO2017161354A1 (en) * 2016-03-17 2017-09-21 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
EP3556380A4 (en) 2016-12-15 2020-05-13 Talengen International Limited METHOD FOR PREVENTING AND TREATING FABRIC OF TISSUE AND ORGAN
JP7214225B2 (ja) * 2016-12-15 2023-01-30 タレンゲン インターナショナル リミテッド 脂肪肝を予防および治療するための方法
US11389515B2 (en) * 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
JP7175270B2 (ja) * 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
CN109125715A (zh) * 2017-06-19 2019-01-04 深圳瑞健生命科学研究院有限公司 一种调控glp-1/glp-1r的方法和药物
JP7335609B2 (ja) * 2017-06-19 2023-08-30 タレンゲン インターナショナル リミテッド Ｇｌｐ－１／ｇｌｐ－１ｒを調節制御する方法および薬剤
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
EP3914288A1 (en) * 2019-01-24 2021-12-01 PreviPharma Consulting GmbH Plasminogen for treating and preventing microthrombosis
EP3812772B1 (en) * 2019-10-24 2025-02-19 Hôpitaux Universitaires de Strasbourg (HUS) Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps
WO2021214320A1 (en) 2020-04-23 2021-10-28 Previpharma Consulting Gmbh Plasminogen for use in treating and preventing lung dysfunction
CN114354929A (zh) * 2022-01-07 2022-04-15 南京鼓楼医院 一种用于监测人体纤溶状态的试剂盒及应用
WO2025049724A1 (en) * 2023-08-29 2025-03-06 Board Of Regents Of The University Of Nebraska Compositions and methods for treating pleural space infections and hemothorax

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (enExample) * 1973-12-18 1977-04-22 Choay Sa
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
WO1994001128A1 (en) * 1992-07-01 1994-01-20 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
WO1994018315A1 (en) * 1993-02-05 1994-08-18 Vascular Laboratories, Inc. Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis
US20030224516A1 (en) * 2002-06-03 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of prox-1 expression
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20050271636A1 (en) * 2002-08-09 2005-12-08 St. Jude Children's Research Hospital, Inc. Diagnostic and therapeutic uses for prox 1
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
EP2056864B1 (en) * 2006-08-28 2013-12-11 Omnio Healer AB Candidates against infection
CA2662083C (en) * 2006-08-28 2016-09-20 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
AU2010270146B9 (en) * 2009-07-10 2015-04-02 Thrombogenics Nv Variants of plasminogen and plasmin
KR20130100290A (ko) * 2010-08-30 2013-09-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 협착성 병변을 위한 전단 제어 방출 및 혈전 용해 치료법
JP6805162B2 (ja) * 2014-12-19 2020-12-23 プロメティック・バイオセラピューティクス・インコーポレイテッドＰｒｏＭｅｔｉｃ ＢｉｏＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プラミノーゲンを含む医薬組成物及びその使用
ES3046932T3 (en) * 2015-12-18 2025-12-02 Talengen Int Ltd Plasminogen preventing or treating diabetic retinopathy

Also Published As

Publication number Publication date
IL258913B (en) 2021-12-01
BR112018008965A8 (pt) 2019-02-26
MY199581A (en) 2023-11-07
CA3002915C (en) 2024-01-16
EP3370760A4 (en) 2019-06-26
CN108289935A (zh) 2018-07-17
US20190231854A1 (en) 2019-08-01
KR20180083348A (ko) 2018-07-20
TW201722463A (zh) 2017-07-01
BR112018008965A2 (pt) 2018-11-21
JP2018533589A (ja) 2018-11-15
EP3370760A1 (en) 2018-09-12
KR102821400B1 (ko) 2025-06-18
CA3002915A1 (en) 2017-05-11
RU2018120182A (ru) 2019-12-04
AU2016347863B2 (en) 2023-11-09
FI3370760T3 (fi) 2025-12-05
RU2018120182A3 (enExample) 2020-04-27
RU2736831C2 (ru) 2020-11-20
MX2018005588A (es) 2018-11-09
TWI801331B (zh) 2023-05-11
NZ742657A (en) 2024-04-26
ZA201802820B (en) 2019-07-31
IL258913A (en) 2018-06-28
AU2016347863A1 (en) 2018-06-07
US11291711B2 (en) 2022-04-05
EP3370760B1 (en) 2025-10-01
WO2017077380A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
JP6878423B2 (ja) プラスミノーゲン欠損症のためのプラスミノーゲン補充療法
Shapiro et al. Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency
EA002496B1 (ru) Способы лечения состояний гиперкоагуляции или приобретенной недостаточности белка с
Hohenfellner et al. Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis
Roldán et al. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis
US20090018082A1 (en) Use of Factor VIIa or Factor VIIa Equivalents for Treating Trauma
US20220160847A1 (en) Method of preventing and/or treating a plurality of diseases
Qin et al. Progress in the treatment of acute fatty liver of pregnancy and management of perioperative anesthesia review
JP2023060011A (ja) 妊娠高血圧腎症の治療方法
JP7515557B2 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
JP2009520696A (ja) 出血性ショックおよびその続発症を治療するための製剤
RU2799764C2 (ru) Лекарственное средство для терапевтического лечения и/или улучшения состояния при сепсисе, сопровождающемся коагулопатией
Karim et al. A Preoperative Evaluation Revealing a Rare Coagulation Factor Deficiency
Armstrong-Wells et al. Neonatal thrombosis
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
Pisciotto Neonatal plasma transfusions
Kalabalik et al. 1323: Use of prothrombin complex concentrate in two patients with major bleed associated with rivaroxaban
JP2014162789A (ja) 羊水塞栓症治療剤
Sergeevich et al. NORTH-WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER II MECHNIKOV
HARRIS et al. 7 Fluid, electrolyte and acid-base balance
Vijay Correlative Study of Fibrinogen Level BMI and Lipid Profile in Type 2 Diabetes Mellitus with Hypertension
Martins e Silva The 4th International Symposium on Clinical Haemorheology: Report and Abstracts

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210428

R150 Certificate of patent or registration of utility model

Ref document number: 6878423

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250